• This document is a corporate presentation of financial results for H1 FY27 (first half of fiscal year 2027) by Beta Drugs Limited.
  • The presentation outlines the company's evolution into a global special formulations company and its blueprint for building enduring brands.
  • No specific event date, time, or management participants were disclosed in the provided data.
  • The company stated that no unpublished price sensitive information (UPSI) will be shared as this is a prepared corporate presentation for information purposes.

Financial Performance Highlights

  • Gross Margins: Increased to 56.2% in H1 FY27 from 51.4% year-over-year
  • Segment Performance:
  • Branded Oncology segment grew 17% year-over-year in H1 FY27
  • Nivian brand recorded 75% year-over-year growth in H1 FY27
  • CMO business grew 21% in H1 FY27 driven by new customer additions
  • API business grew approximately 30% in H1 FY27
  • Export Performance: Filed 76 dossiers and received 35 approvals in H1 FY27
  • Capacity Investments: Invested ~26 crores up to H1 FY27 towards capacity expansion and backward integration

Manufacturing Capacity Details

  • Liquid injections: 13.5 million vials/annum + 35 million vials/annum
  • Lyo injections: 1.8 million vials/annum + 7.8 million vials/annum
  • Tablets: 173.2 million/annum + 70 million/annum
  • Capsules: 45.2 million/annum + 12.6 million/annum
  • API Capacity: 9 MTPA
  • KSM Capacity: 10 MTPA

Business Segment Updates

  • Derma Segment: H1 FY27 impacted by supply chain constraints leading to stockouts; secondary sales PCPM grew 30% to reach >INR 2.54 L; targeting INR 20 crores sales for FY27
  • Export Formulations: Expanding supply relationships and deepening pipeline; supplying NDDS products to CMO customers
  • API Business: Focus on expanding portfolio and achieving regulated market accreditations; backward integration key to EU GMP product filings

Balance Sheet Highlights (Rs Crores)

| Metric | H1'25 | H1'26 | H1'27 |

| Equity Share Capital | 181 | 221 | 475 |

| Borrowings (Long & Short term) | 19 | 146 | 49 |

| Other liabilities | 95 | 121 | 133 |

| Total liabilities | 295 | 488 | 656 |

| Fixed assets (Net) | 66 | 112 | 229 |

| Cash & cash equivalents | 28 | 123 | 104 |

| Other assets | 201 | 254 | 323 |

| Total assets | 295 | 488 | 656 |

Strategic Initiatives

  • Company is on track to accomplish Vision 2030
  • Focus on innovation to drive differentiation with 14 key launches in H1 FY27
  • Expanding prescriber base to accelerate penetration
  • Agreement for "First to launch" product for Mesotherapy in Indian Cosmeceutical market
  • Exclusive agreement with Frezyderm for India to market premium cosmeceuticals
  • Pan-India presence with 79 distributors in North, 42 in South, and 80 in West

Additional Notes

  • This is a corporate presentation dated October 2026 containing forward-looking statements
  • Presentation includes disclaimer about not constituting an offer of securities
  • No financial data was withheld - all disclosed figures are presented above
  • Document contains standard confidentiality and liability disclaimers